5 nov 2019
CPhI Worldwide 2019
Singapore Biotech Pte. Ltd.

Singapore Biotech Pte. Ltd.

Exhibitor at CPhI Worldwide 2019 stand 90B90, Finished Dosage Formulations

About us

Singapore Biotech is a trusted Biologic company that changes lives by making advanced biologics more accessible and more affordable.
The EU-GMP certified manufacturing facilities enable us to deliver world-class quality biosimilars to patients, across the globe.
Utilizing latest manufacturing technologies is our competitive edge to support our international partners to increase uptake of biosimilars in different regions.

Business Model and Partnering Structures at Singapore Biotech:

·         Out licensing
·         Supply and Distribution (API and Finished Product)
·         Technology Transfer
·         Co-Development
·         Contract Manufacturing

Our Target Therapeutic Areas:

·         Neurology (Interferon beta-1a)
·         Oncology & Hematology (Erythropoietin beta, Pegylated filgrastim, Rituximab, Trastuzumab, Bevacizumab and rFactor VII)
·         Gynecology & Endocrinology (Follitropin alfa and Somatropin)
·         Rheumatology (Teriparatide, Adalimumab and Etanercept)

Specs about this supplier

Affiliated categories: Antibodies |Biomanufacturing |Biopharmaceuticals (general category) More

Products featured at CPhI Worldwide 2019

Singapore Biotech Pte. Ltd.

Event information

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany Visit us at stand 90B90